D. M. Mednaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
D. M. Mednaya has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Natalya V. Chebanenko
Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia
10 shared publications - Pavel L. Sokolov
V.F. Voyno-Yasenetsky Scientific and Practical Center of Specialized Medical Care for Children
7 shared publications - Yu.A. Fedotova
Russian Medical Academy of Continuing Professional Education
3 shared publications - Aleksey S. Ivanov
Institute of Biomedical Chemistry, 10 building 8, Pogodinskaya Street, 119121 Moscow, Russia
2 shared publications - Anastasiya Tumilovich
Institute of Bioorganic Chemistry NASB, 5 Building 2, V.F. Kuprevich Street, 220084 Minsk, Belarus
2 shared publications - Andrei A. Gilep
Institute of Biomedical Chemistry, 10 building 8, Pogodinskaya Street, 119121 Moscow, Russia
2 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 21 (3)
D/EE-SWAS syndrome: international criteria, etiological spectrum, and clinical observation experience
Developmental and/or epileptic encephalopathy with spike-wave activation in sleep is a rare but severe group of childhood epileptic syndromes characterized by cognitive regression, behavioral disturbances, and enhancement of epileptiform activity during NREM sleep. The etiopathogenesis is heterogeneous, therapeutic approaches remain debatable, and long-term prognosis is variable. The aim of the work is to present the clinical, etiological, and neurophysiological heterogeneity of developmental and/or epileptic encephalopathy with spike-wave activation in sleep based on a case series and to evaluate the effectiveness of various therapeutic strategies. A retrospective analysis was performed on seven patients (age 6.5–14 years) with verified developmental and/or epileptic encephalopathy with spike-wave activation in sleep followed at a specialized epilepsy center. All patients underwent neurological examination, neuropsychological testing, prolonged sleep electroencephalographic monitoring with spike-wave index assessment, high-resolution brain magnetic resonance imaging, and whole-exome sequencing. High etiological heterogeneity was established: pathogenic variants in CNKSR2, SCN2A, and PACS1 were identified in 3 out of 7 patients; one patient had variants in SMARCC2 and SIN3B; in three cases, the etiology remained unknown. Spike-wave index exceeded 50 % in six patients (up to 100 %). Corticosteroid therapy provided a transient response in 5 out of 6 patients, with relapses upon withdrawal. Introduction of sulthiame resulted in seizure control in 4 patients and spike-wave index reduction in 3. In one patient with drug-resistant epilepsy, vagus nerve stimulation led to seizure freedom for 3 years. Cognitive outcomes were better in patients with epileptic encephalopathy with spike-wave activation in sleep compared to developmental and epileptic encephalopathy with spike-wave activation in sleep. Patients with genetically determined forms retained more severe neurocognitive deficits. Developmental and/or epileptic encephalopathy with spike-wave activation in sleep represents a heterogeneous syndrome requiring a personalized diagnostic and therapeutic approach. Combined therapy with sulthiame and corticosteroids, as well as early consideration of vagus nerve stimulation in refractory patients, may improve outcomes. Further studies are needed to develop unified remission criteria and targeted treatment modalities.
- 13 November 2026
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 21 (3)
Open AccessD/EE-SWAS syndrome: international criteria, etiological spectrum, and clinical observation experience
Developmental and/or epileptic encephalopathy with spike-wave activation in sleep is a rare but severe group of childhood epileptic syndromes characterized by cognitive regression, behavioral disturbances, and enhancement of epileptiform activity during NREM sleep. The etiopathogenesis is heterogeneous, therapeutic approaches remain debatable, and long-term prognosis is variable. The aim of the work is to present the clinical, etiological, and neurophysiological heterogeneity of developmental and/or epileptic encephalopathy with spike-wave activation in sleep based on a case series and to evaluate the effectiveness of various therapeutic strategies. A retrospective analysis was performed on seven patients (age 6.5–14 years) with verified developmental and/or epileptic encephalopathy with spike-wave activation in sleep followed at a specialized epilepsy center. All patients underwent neurological examination, neuropsychological testing, prolonged sleep electroencephalographic monitoring with spike-wave index assessment, high-resolution brain magnetic resonance imaging, and whole-exome sequencing. High etiological heterogeneity was established: pathogenic variants in CNKSR2, SCN2A, and PACS1 were identified in 3 out of 7 patients; one patient had variants in SMARCC2 and SIN3B; in three cases, the etiology remained unknown. Spike-wave index exceeded 50 % in six patients (up to 100 %). Corticosteroid therapy provided a transient response in 5 out of 6 patients, with relapses upon withdrawal. Introduction of sulthiame resulted in seizure control in 4 patients and spike-wave index reduction in 3. In one patient with drug-resistant epilepsy, vagus nerve stimulation led to seizure freedom for 3 years. Cognitive outcomes were better in patients with epileptic encephalopathy with spike-wave activation in sleep compared to developmental and epileptic encephalopathy with spike-wave activation in sleep. Patients with genetically determined forms retained more severe neurocognitive deficits. Developmental and/or epileptic encephalopathy with spike-wave activation in sleep represents a heterogeneous syndrome requiring a personalized diagnostic and therapeutic approach. Combined therapy with sulthiame and corticosteroids, as well as early consideration of vagus nerve stimulation in refractory patients, may improve outcomes. Further studies are needed to develop unified remission criteria and targeted treatment modalities.
- Open Access
- 30 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9754
Fine-Tuning the Processes of Steroid Hormone Biosynthesis: SULT2A1/1E1 and CYP21A2 Interaction
The high physiological activity of steroid hormones requires multilevel regulation of their biosynthesis. Cytosolic sulfotransferases, specifically SULT2A1 and SULT1E1, convert steroid precursors into mobile sulfated depot forms, diverting them from key steroidogenic cytochromes P450. Given the previously demonstrated CYP17A1–SULT interactions, this study aims to verify the hypothesis that CYP21A2 can interact with SULTs and thereby potentially contribute to the regulation of steroid metabolism. Using surface plasmon resonance (SPR) biosensing, in vitro enzymatic activity assays, and in silico molecular modeling, we investigated the interplay between CYP21A2 and SULT2A1/1E1. SPR analysis revealed high-affinity binding between purified recombinant CYP21A2 and SULT2A1/SULT1E1 in vitro in the nanomolar range (9.5 × 10−9 M for SULT2A1 and 1.15 × 10−8 M for SULT1E1). Thermodynamic assessments indicated that the CYP21A2–SULT1E1 complex is entropy-driven, contrasting with the enthalpy-driven CYP17A1–SULT1E1 interaction. Enzymatic assays demonstrated reciprocal modulatory effects: CYP21A2 exerted a stimulatory effect on pregnenolone sulfation by SULTs, whereas SULT2A1 moderately inhibited CYP21A2 activity. Molecular modeling of binary complexes predicted structural interfaces and continuous intraprotein channels connecting the enzymes’ active sites. These findings suggest that CYP–SULT interactions may contribute to the fine-tuning of steroid hormone biosynthesis. These findings raise the possibility that CYP–SULT interactions may form part of a broader regulatory network, acting as metabolic switches that dictate the balance between downstream corticosteroid pathways and structural sequestration into sulfated pools.
- 30 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9754
Open AccessFine-Tuning the Processes of Steroid Hormone Biosynthesis: SULT2A1/1E1 and CYP21A2 Interaction
The high physiological activity of steroid hormones requires multilevel regulation of their biosynthesis. Cytosolic sulfotransferases, specifically SULT2A1 and SULT1E1, convert steroid precursors into mobile sulfated depot forms, diverting them from key steroidogenic cytochromes P450. Given the previously demonstrated CYP17A1–SULT interactions, this study aims to verify the hypothesis that CYP21A2 can interact with SULTs and thereby potentially contribute to the regulation of steroid metabolism. Using surface plasmon resonance (SPR) biosensing, in vitro enzymatic activity assays, and in silico molecular modeling, we investigated the interplay between CYP21A2 and SULT2A1/1E1. SPR analysis revealed high-affinity binding between purified recombinant CYP21A2 and SULT2A1/SULT1E1 in vitro in the nanomolar range (9.5 × 10−9 M for SULT2A1 and 1.15 × 10−8 M for SULT1E1). Thermodynamic assessments indicated that the CYP21A2–SULT1E1 complex is entropy-driven, contrasting with the enthalpy-driven CYP17A1–SULT1E1 interaction. Enzymatic assays demonstrated reciprocal modulatory effects: CYP21A2 exerted a stimulatory effect on pregnenolone sulfation by SULTs, whereas SULT2A1 moderately inhibited CYP21A2 activity. Molecular modeling of binary complexes predicted structural interfaces and continuous intraprotein channels connecting the enzymes’ active sites. These findings suggest that CYP–SULT interactions may contribute to the fine-tuning of steroid hormone biosynthesis. These findings raise the possibility that CYP–SULT interactions may form part of a broader regulatory network, acting as metabolic switches that dictate the balance between downstream corticosteroid pathways and structural sequestration into sulfated pools.
- 22 October 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (9)
Clinical heterogeneity and prediction complexity associated with nucleotide sequence abnormalities in the SCN2A gene
Numerous variants of the SCN2A gene have been identified, including missense mutations, deletions, insertions, frameshifting, nonsense mutations, and splice site mutations. The emergence of severe phenotypes is generally associated with de novo and missense variants. The clinical manifestations linked to SCN2A abnormalities exhibit considerable diversity, including varying severities of epileptic episodes with onset in neonatal or subsequent periods, autism spectrum disorders, schizophrenia (including catatonic manifestations), and episodic ataxia. With rare exceptions, all identified phenotypes are associated with developmental delay or regression. The phenotypic diversity associated with SCN2A genetic variants is influenced by the extensive expression of the gene in neuronal populations across various brain regions, its impact on numerous processes critical for the development and functionality of the central nervous system, the distinct localization of mutations within the gene, and the type of mutations (missense, nonsense, frameshift). Variants in nucleotide sequences may increase or decrease gene function (gain-of-function and loss-of-function, respectively) and are associated with ion channel activity influenced by neuroglial effects. An analysis of four cases of SCN2A genetic variants (one case shown to be associated with DENND5A) demonstrated a high efficacy in predicting phenotypes based on existing descriptions of nucleotide sequence abnormalities. However, predictions proved ineffective for similar mutations and for de novo mutations. It is concluded that advances in predicting the phenotypic outcomes of genomic abnormalities depend on the accumulation of clinical data and a thorough investigation of the molecular mechanisms governing gene function.
- 22 October 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (9)
Clinical heterogeneity and prediction complexity associated with nucleotide sequence abnormalities in the SCN2A gene
Numerous variants of the SCN2A gene have been identified, including missense mutations, deletions, insertions, frameshifting, nonsense mutations, and splice site mutations. The emergence of severe phenotypes is generally associated with de novo and missense variants. The clinical manifestations linked to SCN2A abnormalities exhibit considerable diversity, including varying severities of epileptic episodes with onset in neonatal or subsequent periods, autism spectrum disorders, schizophrenia (including catatonic manifestations), and episodic ataxia. With rare exceptions, all identified phenotypes are associated with developmental delay or regression. The phenotypic diversity associated with SCN2A genetic variants is influenced by the extensive expression of the gene in neuronal populations across various brain regions, its impact on numerous processes critical for the development and functionality of the central nervous system, the distinct localization of mutations within the gene, and the type of mutations (missense, nonsense, frameshift). Variants in nucleotide sequences may increase or decrease gene function (gain-of-function and loss-of-function, respectively) and are associated with ion channel activity influenced by neuroglial effects. An analysis of four cases of SCN2A genetic variants (one case shown to be associated with DENND5A) demonstrated a high efficacy in predicting phenotypes based on existing descriptions of nucleotide sequence abnormalities. However, predictions proved ineffective for similar mutations and for de novo mutations. It is concluded that advances in predicting the phenotypic outcomes of genomic abnormalities depend on the accumulation of clinical data and a thorough investigation of the molecular mechanisms governing gene function.
- Open Access
- 28 September 2026
- Published by MDPI AG in Preprints.org
Fine-Tuning the Processes of Steroid Hormone Biosynthesis: SULT2A1/1E1 and CYP21A2 Interaction
The high physiological activity of steroid hormones requires multilevel regulation of their biosynthesis. Cytosolic sulfotransferases, specifically SULT2A1 and SULT1E1, convert steroid precursors into mobile sulfated depot forms, diverting them from key steroidogenic cytochromes P450. Given the previously demonstrated CYP17A1–SULT interactions, this study aims to verify the hypothesis that CYP21A2 also interacts with SULTs to co-regulate steroid biosynthesis. Using surface plasmon resonance (SPR) biosensing, in vitro enzymatic activity assays, and in silico molecular modeling, we investigated the interplay between CYP21A2 and SULT2A1/1E1. SPR analysis revealed direct, high-affinity protein–protein interactions in the nanomolar range. Thermodynamic assessments indicated that the CYP21A2–SULT1E1 complex is entropy-driven, contrasting with the enthalpy-driven CYP17A1–SULT1E1 interaction. Enzymatic assays demonstrated reciprocal modulatory effects: CYP21A2 exerted a stimulatory effect on pregnenolone sulfation by SULTs, whereas SULT2A1 moderately inhibited CYP21A2 activity. Molecular modeling of binary complexes predicted structural interfaces and continuous intraprotein channels connecting the enzymes' active sites. These findings suggest that CYP–SULT interactions contribute to the fine-tuning of steroid hormone biosynthesis. We propose that these enzymes participate in a highly organized multiprotein network, acting as metabolic switches that dictate the balance between downstream corticosteroid pathways and structural sequestration into sulfated pools.
- 28 September 2026
- Published by MDPI AG in Preprints.org
Open AccessFine-Tuning the Processes of Steroid Hormone Biosynthesis: SULT2A1/1E1 and CYP21A2 Interaction
The high physiological activity of steroid hormones requires multilevel regulation of their biosynthesis. Cytosolic sulfotransferases, specifically SULT2A1 and SULT1E1, convert steroid precursors into mobile sulfated depot forms, diverting them from key steroidogenic cytochromes P450. Given the previously demonstrated CYP17A1–SULT interactions, this study aims to verify the hypothesis that CYP21A2 also interacts with SULTs to co-regulate steroid biosynthesis. Using surface plasmon resonance (SPR) biosensing, in vitro enzymatic activity assays, and in silico molecular modeling, we investigated the interplay between CYP21A2 and SULT2A1/1E1. SPR analysis revealed direct, high-affinity protein–protein interactions in the nanomolar range. Thermodynamic assessments indicated that the CYP21A2–SULT1E1 complex is entropy-driven, contrasting with the enthalpy-driven CYP17A1–SULT1E1 interaction. Enzymatic assays demonstrated reciprocal modulatory effects: CYP21A2 exerted a stimulatory effect on pregnenolone sulfation by SULTs, whereas SULT2A1 moderately inhibited CYP21A2 activity. Molecular modeling of binary complexes predicted structural interfaces and continuous intraprotein channels connecting the enzymes' active sites. These findings suggest that CYP–SULT interactions contribute to the fine-tuning of steroid hormone biosynthesis. We propose that these enzymes participate in a highly organized multiprotein network, acting as metabolic switches that dictate the balance between downstream corticosteroid pathways and structural sequestration into sulfated pools.
- 21 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (10) , 80-87
Epileptic encephalopathy associated with a mutation in the KCNT1 gene
According to the World Health Organization, more than 50 million people worldwide have epilepsy, and about 5 million new cases are reported annually. According to other data, the number of patients exceeds 70.000.000, highlighting the relevance of this condition. Studies of developmental epileptic encephalopathies leading to early disability are particularly relevant. About 900 gene mutations associated with different types of epilepsy have been identified so far. One of the prominent «channelopathy genes» representatives is KCNT1, coding the largest subunit of the sodium-activated potassium channel, KNa1.1. Its mutations are associated with many neurological disorders, such as leukodystrophy, leukoencephalopathy, West syndrome, Ohtahara syndrome, early myoclonic encephalopathy, focal epilepsy, and multifocal epilepsy. A clinical case of a typical course of KCNT1-associated epilepsy with early onset (in the first half of life), focal and asynchronous paroxysms, psychomotor retardation, and drug resistance is presented. The effectiveness of the anticonvulsants used and the nature of pharmacological resistance were analyzed. The applicability of four «Drug Resistance Hypotheses» to this case is shown: genetic, since the pathogenesis of this particular case is based on a change in the properties of potassium channels; a change in the sensitivity of the anticonvulsant targets explains the intermittent (according to Schmidt and Löscher) nature of resistance. The «Neural Networks Hypothesis» is illustrated by the change of encephalographic indicators from multifocal epileptiform activity with an intact background to pronounced dysrhythmia with periods of the «burst-suppression» pattern after several months. All these features, combined, refer to the «Intrinsic Severity» hypothesis by Rogawski and Johnson, since the child’s disease was initially severe due to the intensity and frequency of epileptic seizures. As a result, a conclusion was made about the complexity of the refractoriness formation mechanisms, even in cases with a simple and understandable pathogenesis of channelopathy.
- 21 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (10) , 80-87
Epileptic encephalopathy associated with a mutation in the KCNT1 gene
According to the World Health Organization, more than 50 million people worldwide have epilepsy, and about 5 million new cases are reported annually. According to other data, the number of patients exceeds 70.000.000, highlighting the relevance of this condition. Studies of developmental epileptic encephalopathies leading to early disability are particularly relevant. About 900 gene mutations associated with different types of epilepsy have been identified so far. One of the prominent «channelopathy genes» representatives is KCNT1, coding the largest subunit of the sodium-activated potassium channel, KNa1.1. Its mutations are associated with many neurological disorders, such as leukodystrophy, leukoencephalopathy, West syndrome, Ohtahara syndrome, early myoclonic encephalopathy, focal epilepsy, and multifocal epilepsy. A clinical case of a typical course of KCNT1-associated epilepsy with early onset (in the first half of life), focal and asynchronous paroxysms, psychomotor retardation, and drug resistance is presented. The effectiveness of the anticonvulsants used and the nature of pharmacological resistance were analyzed. The applicability of four «Drug Resistance Hypotheses» to this case is shown: genetic, since the pathogenesis of this particular case is based on a change in the properties of potassium channels; a change in the sensitivity of the anticonvulsant targets explains the intermittent (according to Schmidt and Löscher) nature of resistance. The «Neural Networks Hypothesis» is illustrated by the change of encephalographic indicators from multifocal epileptiform activity with an intact background to pronounced dysrhythmia with periods of the «burst-suppression» pattern after several months. All these features, combined, refer to the «Intrinsic Severity» hypothesis by Rogawski and Johnson, since the child’s disease was initially severe due to the intensity and frequency of epileptic seizures. As a result, a conclusion was made about the complexity of the refractoriness formation mechanisms, even in cases with a simple and understandable pathogenesis of channelopathy.
- 21 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (10) , 136-141
Developmental epileptic encephalopathy caused by a de novo mutation in the SCN8A gene
Developmental epileptic encephalopathy is characterized by a malignant course of refractory epilepsy and a growing defect in mental and motor development. To date, determinant genes have been identified for most of these conditions. This condition is also caused by mutations in the SCN8A gene of a voltage-gated sodium channel, which is detected in about 1% of children with early infantile epileptic encephalopathies. SCN8A gene mutations result in both an increase (gain-of-function, GOF mutation) and a decrease (loss-of-function, LOF mutation) in NaV1.6 sodium channel function, leading to a decrease in current amplitude and a depolarizing shift. With GOF mutation, hypotension, cerebral visual dysfunction, dyskinesia, ataxia, and epileptic seizures are mainly present as bilateral tonic and focal seizures and, in most cases, lead to epileptic encephalopathy. With the LOF mutation, seizures (absences, bilateral tonic-clonic myoclonic seizures) may not appear, while cognitive impairment, movement disorders, and autistic traits are present. Anticonvulsant regimens include non-selective sodium channel blockers, GABA agonists, Na+ and Ca2+ channel blockers, and other agents. A specific feature of the phenotype is a relatively high probability of exacerbation of the epilepsy during anticonvulsant selection, which requires special care and caution from the doctor. As an illustration of the most typical features of the condition, a clinical case of severe refractory epilepsy with a developmental disorder in an infant is presented. The disease progressed despite all attempts to select therapy. Treatment with corticosteroids gave a temporary effect, and when the drug was discontinued, the frequency and severity of seizures increased, suggesting the GOF scenario; however, genetic confirmation was inaccessible. The authors believe that the prospects for treating such conditions are determined primarily by progress in the development of new drugs, including oligonucleotides and selective inhibitors of NaV1.6 channels.
- 21 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (10) , 136-141
Developmental epileptic encephalopathy caused by a de novo mutation in the SCN8A gene
Developmental epileptic encephalopathy is characterized by a malignant course of refractory epilepsy and a growing defect in mental and motor development. To date, determinant genes have been identified for most of these conditions. This condition is also caused by mutations in the SCN8A gene of a voltage-gated sodium channel, which is detected in about 1% of children with early infantile epileptic encephalopathies. SCN8A gene mutations result in both an increase (gain-of-function, GOF mutation) and a decrease (loss-of-function, LOF mutation) in NaV1.6 sodium channel function, leading to a decrease in current amplitude and a depolarizing shift. With GOF mutation, hypotension, cerebral visual dysfunction, dyskinesia, ataxia, and epileptic seizures are mainly present as bilateral tonic and focal seizures and, in most cases, lead to epileptic encephalopathy. With the LOF mutation, seizures (absences, bilateral tonic-clonic myoclonic seizures) may not appear, while cognitive impairment, movement disorders, and autistic traits are present. Anticonvulsant regimens include non-selective sodium channel blockers, GABA agonists, Na+ and Ca2+ channel blockers, and other agents. A specific feature of the phenotype is a relatively high probability of exacerbation of the epilepsy during anticonvulsant selection, which requires special care and caution from the doctor. As an illustration of the most typical features of the condition, a clinical case of severe refractory epilepsy with a developmental disorder in an infant is presented. The disease progressed despite all attempts to select therapy. Treatment with corticosteroids gave a temporary effect, and when the drug was discontinued, the frequency and severity of seizures increased, suggesting the GOF scenario; however, genetic confirmation was inaccessible. The authors believe that the prospects for treating such conditions are determined primarily by progress in the development of new drugs, including oligonucleotides and selective inhibitors of NaV1.6 channels.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (7) , 51-55
Epilepsy with PCDH19 mutation: polypharmacy as a consequence of the complexity and diversity of pathogenesis mechanisms
Mutations in the human PCDH19 gene lead to epileptic encephalopathy of early childhood. It is characterized by the early onset of serial seizures, cognitive impairment and behavioral disorders (including autistic personality traits). In most cases, difficulties arise in selecting therapy due to pharmacoresistance. The pathogenesis of the disease is complex. The data available to us at the moment from numerous studies present the pathogenesis of «PCDH19 syndrome» as multi-level, affecting both the epigenetic support of cell life, and development of stem cells and progenitor cells in the process of neuroontogenesis, and the influence on the neurotransmitter mechanisms of the brain, and disruption of the formation of neural networks with an inevitable increase in the excitability of the cerebral cortex as a whole, and local changes in the highly labile regulatory structures of the hippocampal region. And it is not surprising that all these changes entail not only (and perhaps not so much) epileptization, but a profound disruption of the regulation of brain activity, accompanied by autism spectrum disorders, more profound disorders in the form of schizophrenia or cyclothymia, and the formation of delayed psychomotor development. A «side branch» of these pathogenetic processes can also be considered the participation of PCDH19 dysfunctions in certain variants of oncogenesis. The need for polypharmacy (in most cases) confirms the diversity of mechanisms involved in the pathogenesis of the disease and makes the prospects for the development of effective and rational treatment regimens very vague. Cautious optimism is caused only by attempts at relatively specific treatment with ganaxolone.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (7) , 51-55
Epilepsy with PCDH19 mutation: polypharmacy as a consequence of the complexity and diversity of pathogenesis mechanisms
Mutations in the human PCDH19 gene lead to epileptic encephalopathy of early childhood. It is characterized by the early onset of serial seizures, cognitive impairment and behavioral disorders (including autistic personality traits). In most cases, difficulties arise in selecting therapy due to pharmacoresistance. The pathogenesis of the disease is complex. The data available to us at the moment from numerous studies present the pathogenesis of «PCDH19 syndrome» as multi-level, affecting both the epigenetic support of cell life, and development of stem cells and progenitor cells in the process of neuroontogenesis, and the influence on the neurotransmitter mechanisms of the brain, and disruption of the formation of neural networks with an inevitable increase in the excitability of the cerebral cortex as a whole, and local changes in the highly labile regulatory structures of the hippocampal region. And it is not surprising that all these changes entail not only (and perhaps not so much) epileptization, but a profound disruption of the regulation of brain activity, accompanied by autism spectrum disorders, more profound disorders in the form of schizophrenia or cyclothymia, and the formation of delayed psychomotor development. A «side branch» of these pathogenetic processes can also be considered the participation of PCDH19 dysfunctions in certain variants of oncogenesis. The need for polypharmacy (in most cases) confirms the diversity of mechanisms involved in the pathogenesis of the disease and makes the prospects for the development of effective and rational treatment regimens very vague. Cautious optimism is caused only by attempts at relatively specific treatment with ganaxolone.
- Open Access
- 15 January 2024
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 19 (1) , 48‑53
Epilepsy and congenital cerebral palsy: Parallels between the location of genome anomalies and clinical manifestations
Progress in molecular genetics is gradually leading to a radical revision of the understanding of the nature of not only recognized genetically determined diseases, but also those whose genetic nature has only been assumed. More and more information is emerging about polygenic and/or multifactorial diseases. The authors P.L. Sokolov and N.V. Chebanenko in 2022 proposed the concept of a neurotropic genome and the classification of genes, according to their “areas of responsibility” – points of application of determinant activity. There is a growing number of scientific works on the dependence of the pathological phenotype on the nature of the mutation and its localization along the gene.In this article, using the example of Wolf–Hirschhorn syndrome, variants of the dependence of the phenotype on the location of the genome abnormality are considered. A case of a disease from the authors’ practice, in which epilepsy and cerebral palsy predominate, is presented; the phenotype is analyzed with the nature and location of the identified genetic anomaly. The authors make assumption about the connection between the nature and location of the genome anomaly and the characteristics of the phenotype.
- 15 January 2024
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 19 (1) , 48‑53
Open AccessEpilepsy and congenital cerebral palsy: Parallels between the location of genome anomalies and clinical manifestations
Progress in molecular genetics is gradually leading to a radical revision of the understanding of the nature of not only recognized genetically determined diseases, but also those whose genetic nature has only been assumed. More and more information is emerging about polygenic and/or multifactorial diseases. The authors P.L. Sokolov and N.V. Chebanenko in 2022 proposed the concept of a neurotropic genome and the classification of genes, according to their “areas of responsibility” – points of application of determinant activity. There is a growing number of scientific works on the dependence of the pathological phenotype on the nature of the mutation and its localization along the gene.In this article, using the example of Wolf–Hirschhorn syndrome, variants of the dependence of the phenotype on the location of the genome abnormality are considered. A case of a disease from the authors’ practice, in which epilepsy and cerebral palsy predominate, is presented; the phenotype is analyzed with the nature and location of the identified genetic anomaly. The authors make assumption about the connection between the nature and location of the genome anomaly and the characteristics of the phenotype.
- Open Access
- 26 September 2023
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 11 (3) , 348-360
Current Approaches to Assessing the Safety and Efficacy of Lamotrigine in Children and Adolescents with Epileptic Syndromes Associated with Focal Seizures
Scientific relevance. Epileptic syndromes associated with focal seizures often develop in children and adolescents and may be accompanied by cognitive impairment, mental disorders, and endocrine disorders, which require additional medication apart from anti-epileptic medicinal products. Currently, the selection of safe and effective therapies for epileptic syndromes, especially in paediatric populations, is a pressing challenge for epileptology.Aim.This study aimed at a comprehensive assessment of the safety and efficacy of lamotrigine in therapeutic doses for children and adolescents with epileptic syndromes associated with focal seizures.Materials and methods.A total of 53 patients aged 3 to 18 years with various epileptic syndromes associated with focal seizures were under observation in 2020–2023. During this period, 37 patients (69.8%) received monotherapy with lamotrigine, and 16 patients (30.2%) received combination therapy including lamotrigine and two or more other medicinal products. When evaluating the safety and efficacy of pharmacotherapy in adolescent patients, the authors selectively used the Software for Post-marketing Studies of Anti-epileptic Medicinal Products developed at the Scientific Centre for Expert Evaluation of Medicinal Products.Results.With lamotrigine, the highest rate of complete clinical remission was observed in patients with focal epilepsy with onset in childhood and adolescence (90.9% of cases). For structural focal epilepsy, 16.7% of patients achieved complete freedom from seizures, and 50% demonstrated a pronounced response to treatment. However, patients with epilepsy due to local structural changes in the neocortex (33.3% of cases) had a prognosis of severe epilepsy. For epileptic encephalopathies with onset in childhood, 66.7% of patients achieved a ≥50% reduction in the frequency of seizures. Seizure reduction improved the quality of life of patients and their parents, especially of those with a long history of unsuccessful treatment attempts. There were no adverse reactions associated with lamotrigine except those listed in the summary of product characteristics. The Software for Post-marketing Studies of Anti-epileptic Medicinal Products provided a means for scoring and plotting the changes in the condition of adolescents without severe cognitive and memory impairment undergoing lamotrigine treatment.Conclusions.According to the study results, lamotrigine is highly effective and has a favourable safety profile in patients with early-onset epileptic syndromes associated with focal seizures. Moreover, lamotrigine is applicable to the treatment of attention, memory, expressive speech disorders, and aggressive behaviour. Therefore, lamotrigine may be recommended for treating children and adolescents with comorbid epileptic syndromes and cognitive and emotional disorders. Specialised software improves the quality of real-world evidence regarding the safety and efficacy of anti-epileptic medication.
- 26 September 2023
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 11 (3) , 348-360
Open AccessCurrent Approaches to Assessing the Safety and Efficacy of Lamotrigine in Children and Adolescents with Epileptic Syndromes Associated with Focal Seizures
Scientific relevance. Epileptic syndromes associated with focal seizures often develop in children and adolescents and may be accompanied by cognitive impairment, mental disorders, and endocrine disorders, which require additional medication apart from anti-epileptic medicinal products. Currently, the selection of safe and effective therapies for epileptic syndromes, especially in paediatric populations, is a pressing challenge for epileptology.Aim.This study aimed at a comprehensive assessment of the safety and efficacy of lamotrigine in therapeutic doses for children and adolescents with epileptic syndromes associated with focal seizures.Materials and methods.A total of 53 patients aged 3 to 18 years with various epileptic syndromes associated with focal seizures were under observation in 2020–2023. During this period, 37 patients (69.8%) received monotherapy with lamotrigine, and 16 patients (30.2%) received combination therapy including lamotrigine and two or more other medicinal products. When evaluating the safety and efficacy of pharmacotherapy in adolescent patients, the authors selectively used the Software for Post-marketing Studies of Anti-epileptic Medicinal Products developed at the Scientific Centre for Expert Evaluation of Medicinal Products.Results.With lamotrigine, the highest rate of complete clinical remission was observed in patients with focal epilepsy with onset in childhood and adolescence (90.9% of cases). For structural focal epilepsy, 16.7% of patients achieved complete freedom from seizures, and 50% demonstrated a pronounced response to treatment. However, patients with epilepsy due to local structural changes in the neocortex (33.3% of cases) had a prognosis of severe epilepsy. For epileptic encephalopathies with onset in childhood, 66.7% of patients achieved a ≥50% reduction in the frequency of seizures. Seizure reduction improved the quality of life of patients and their parents, especially of those with a long history of unsuccessful treatment attempts. There were no adverse reactions associated with lamotrigine except those listed in the summary of product characteristics. The Software for Post-marketing Studies of Anti-epileptic Medicinal Products provided a means for scoring and plotting the changes in the condition of adolescents without severe cognitive and memory impairment undergoing lamotrigine treatment.Conclusions.According to the study results, lamotrigine is highly effective and has a favourable safety profile in patients with early-onset epileptic syndromes associated with focal seizures. Moreover, lamotrigine is applicable to the treatment of attention, memory, expressive speech disorders, and aggressive behaviour. Therefore, lamotrigine may be recommended for treating children and adolescents with comorbid epileptic syndromes and cognitive and emotional disorders. Specialised software improves the quality of real-world evidence regarding the safety and efficacy of anti-epileptic medication.
- Open Access
- 15 April 2023
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 18 (2-3) , 22-30
Genetic determinism of epilepsy refractoriness in patients with congenital cerebral p
Background. In the phenotype of cerebral palsy, motor and mental disorders are often accompanied by epilepsy. Congenital epilepsy has been intensively researched in recent years. Special attention is drawn to epilepsy caused by congenital disturbance of the excitability of the neuronal membrane due to canalopathies.Aim. To analyze a large number of genes associated with the development of the cerebral palsy phenotype and distribute them according to determinable traits.Materials and methods. The results of clinical and genetic analysis of 136 cases of cerebral palsy with epilepsy are presented. The patients were divided into groups according to the syndromes according to the classification of cerebral palsy. Epileptic syndromes were divided into three groups: focal childhood epilepsy with structural brain changes and benign epileptiform discharges in electroencephalogram – 41 (30.1 %) cases, structural focal epilepsy – 37 (27.2 %) cases, epileptic encephalopathies – 58 (42.7 %) cases. Pathogenic variants in genes were confirmed by next generation sequencing Sanger methods of venous blood.Results. The performed risk analysis showed that in the presence of disorders in genes attributed to the group of regulation of the formation and functioning of the cytoskeleton, the risk of lack of remission is significantly lower than in other dominants, while abnormalities in genes attributed to the group of regulation of the function of the mitochondrial apparatus significantly increase the risks of failure to achieve remission and need in polytherapy.Conclusion. Probably, the violation of energy metabolism in the cell neutralizes the stabilization of the neuronal membrane under the action of anticonvulsants. The determinant of the formation and functioning of the cytoskeleton, according to our preliminary data, is largely associated with the formation of malformations of the brain. In this case, the refractoriness of epilepsy may be secondary and determined by the severity of structural changes in the brain
- 15 April 2023
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 18 (2-3) , 22-30
Open AccessGenetic determinism of epilepsy refractoriness in patients with congenital cerebral p
Background. In the phenotype of cerebral palsy, motor and mental disorders are often accompanied by epilepsy. Congenital epilepsy has been intensively researched in recent years. Special attention is drawn to epilepsy caused by congenital disturbance of the excitability of the neuronal membrane due to canalopathies.Aim. To analyze a large number of genes associated with the development of the cerebral palsy phenotype and distribute them according to determinable traits.Materials and methods. The results of clinical and genetic analysis of 136 cases of cerebral palsy with epilepsy are presented. The patients were divided into groups according to the syndromes according to the classification of cerebral palsy. Epileptic syndromes were divided into three groups: focal childhood epilepsy with structural brain changes and benign epileptiform discharges in electroencephalogram – 41 (30.1 %) cases, structural focal epilepsy – 37 (27.2 %) cases, epileptic encephalopathies – 58 (42.7 %) cases. Pathogenic variants in genes were confirmed by next generation sequencing Sanger methods of venous blood.Results. The performed risk analysis showed that in the presence of disorders in genes attributed to the group of regulation of the formation and functioning of the cytoskeleton, the risk of lack of remission is significantly lower than in other dominants, while abnormalities in genes attributed to the group of regulation of the function of the mitochondrial apparatus significantly increase the risks of failure to achieve remission and need in polytherapy.Conclusion. Probably, the violation of energy metabolism in the cell neutralizes the stabilization of the neuronal membrane under the action of anticonvulsants. The determinant of the formation and functioning of the cytoskeleton, according to our preliminary data, is largely associated with the formation of malformations of the brain. In this case, the refractoriness of epilepsy may be secondary and determined by the severity of structural changes in the brain